Hot Topics in Hematologic Malignancies in 2018

Hot Topics in Hematologic Malignancies in 2018

A Close Look at DLBCL, AML, and CLL

Not a member of My prIME? Join now for instant access.

Meeting Overview

Stay current on hot topics in hematologic malignancies with our live satellite symposium. The advent of targeted therapies and immunotherapy has led to a vast change in the treatment possibilities for acute myeloid leukemia (AML), diffuse large B-cell lymphoma (DLBCL), and chronic lymphocytic leukemia (CLL). This interactive symposium will feature focused discussion on the newest approved agents in these hematologic malignancies and provide the latest clinical trial updates on novel agents. Join us in Stockholm!

A prIME Oncology satellite symposium to be held at the 23rd Congress of the European Hematology Association.

Date and Location

Thursday, 14 June 2018
19.00 – 21.00

Room: A9
Mässvägen 1
Älvsjö, Sweden



Thursday, 14 June 2018
19.00 – 21.00



Älvsjö, Sweden



2.0 European CME Credits

Thursday, 14 June

19.00 Welcome and introduction
Hagop Kantarjian, MD
19.05 Current state-of-the-art therapy for DLBCL in 2018
Christian Gisselbrecht, MD, PhD
19.15 New targeted therapies on the horizon for DLBCL
Christian Gisselbrecht, MD, PhD
19.35 Questions from the audience on DLBCL
19.40 Current state-of-the-art therapy for AML in 2018
Hagop Kantarjian, MD
19.50 New targeted therapies on the horizon for AML
Hagop Kantarjian, MD
20.10 Questions from the audience on AML
20.15 Current state-of-the-art therapy for CLL in 2018
Anders Österborg, MD, PhD
20.25 New targeted therapies on the horizon for CLL in 2018
Anders Österborg, MD, PhD
20.45 Questions from the audience on CLL
20.50 Closing remarks
21.00 Adjourn


  • Hagop M. Kantarjian, MDThe University of Texas
    MD Anderson Cancer Center
    Houston, Texas, United States
  • Faculty

  • Christian Gisselbrecht, MD, PhDHôpital Saint-Louis
    Paris, France
  • Anders Österborg, MD, PhDKarolinska University Hospital
    Stockholm, Sweden

This educational activity has been designed for hematologists, hematologist/oncologists, and other healthcare providers who treat patients with hematologic malignancies.

After successful completion of this educational activity, participants should be able to:

  • Describe the mechanisms of action of novel targeted and immunologic therapies for AML, DLBCL, and CLL
  • Identify ongoing clinical studies investigating emerging targeted and immunologic therapies for AML, DLBCL, and CLL

This educational activity is supported by grants from Helsinn Healthcare SA; Karyopharm Therapeutics; and TG Therapeutics, Inc.

Continuing Education

Hot Topics in Hematologic Malignancies in 2018: A Close Look at DLBCL, AML, and CLL, held in Stockholm, Sweden, on 14 June 2018, has been accredited by the European Accreditation Council for Continuing Medical Education (EACCME®) with 2.0 European CME credits (ECMEC®s). Each medical specialist should claim only those hours of credit that he/she actually spent in the educational activity.

Through an agreement between the Union Européenne des Médecins Spécialistes and the American Medical Association, physicians may convert EACCME® credits to an equivalent number of AMA PRA Category 1 Credits™. Information on the process to convert EACCME® credit to AMA credit can be found at

Live educational activities, occurring outside of Canada, recognized by the UEMS-EACCME® for ECMEC®s are deemed to be Accredited Group Learning Activities (Section 1) as defined by the Maintenance of Certification Program of The Royal College of Physicians and Surgeons of Canada.

Good CME

Hot Topics in Hematologic Malignancies in 2018 - prIME Oncology


This activity is provided by prIME Oncology.

Sunshine Act/EFPIA

prIME Oncology complies with all Sunshine Act reporting requirements as outlined by CMS and applicable manufacturers and with EFPIA Disclosure Code reporting requirements.


Disclosure of Relevant Financial Relationships

prIME Oncology assesses the relevant financial relationships of its instructors, planners, managers, and other individuals who are in a position to control the content of CME activities. Any potential conflicts of interest that are identified are thoroughly vetted by prIME Oncology for fairness, balance, and scientific objectivity of data, as well as patient care recommendations. prIME Oncology is committed to providing its learners with high-quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial entity.


Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Disclosure Regarding Unlabeled Use

This activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration or European Medicines Agency. Please refer to the official prescribing information for each product discussed for discussions of approved indications, contraindications, and warnings.